In contrast, in a study in 145 pediatric T-ALL patients treated with the MRC UKALL2003 trial, neither PTEN nor RAS significantly impacted on outcome, and none of these mutations changed the highly favorable outcome of patients with double NOTCH1/FBXW7 mutations (29). This evidence concerns the gene PTEN and acute lymphoblastic leukemia.